Despite the number of drugs currently in the pipeline for the treatment of systemic lupus erythematosus (SLE), the panelists raise concerns about unaddressed factors that may continue to impede a clinician’s decision to recommend a treatment option to a patient.
Michelle Petri, MD, MPH, explains that newly-approved therapy options still lack personalized biomarkers and do not provide important long-term outcomes data that help professionals make decisions about treatment for patients with SLE.
Patrick F. Fogarty, MD, further explains that when defining the value of medical therapy, an economic consideration continues to stand in the way of treatment recommendations.
Without addressing these issues, Dr Petri and Dr Fogarty agree that when selecting appropriate therapy for a patient, and when considering the costs associated with a treatment option, it is important to individualize therapy for patients with SLE.
Robert F. Kennedy Jr Faces Senate Inquiry Over Deep Cuts to HHS Impacting FDA, CDC, NIH, CMS
April 2nd 2025A bipartisan letter from lawmakers questions the legality of Robert F. Kennedy Jr's HHS changes and the lack of clear communication regarding their potential impact on American health.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
AI in Health Care: Closing the Revenue Cycle Gap
April 1st 2025This commentary explores the current state, challenges, and potential of artificial intelligence (AI) in health care revenue cycle management, emphasizing collaboration, data standardization, and targeted implementation to enhance adoption.
Read More